In a 74-year-old man who received external-beam radiation therapy one year ago for Gleason 7 prostate cancer and now has a PSA of 1.6 ng/mL, when is the expected PSA nadir and what value is anticipated?

PSA Nadir Timing and Expected Value After External Beam Radiation for Gleason 7 Prostate Cancer

Your patient's PSA of 1.6 ng/mL at one year post-radiation is still declining toward nadir, which typically occurs between 18-30 months after external beam radiotherapy, with an expected nadir value ideally ≤0.7 ng/mL for optimal long-term control. 1

Expected Timing of PSA Nadir

The PSA nadir following external beam radiation therapy does not occur quickly—it continues to decline during the first year but may not reach its lowest point until 18 to 30 months after treatment completion. 1

• The median time to reach PSA nadir after external beam radiotherapy is approximately 1.9 years (23 months) in patients who maintain biochemical control 2
• Patients who achieve nadir at ≥2.0 years have significantly better outcomes than those reaching nadir earlier 2
• A longer time to nadir (≥24 months) is associated with 75% 8-year biochemical control compared to only 27% when nadir occurs within 6 months 3
• PSA levels continue to decline for more than five years after brachytherapy, though your patient received external beam therapy 1

Expected Nadir Value

A PSA nadir ≤0.7 ng/mL at five years is a reasonable target after external beam radiotherapy. 1

Prognostic Significance of Different Nadir Levels:

• Nadir ≤0.4 ng/mL: 78% 5-year biochemical control rate 2
• Nadir 0.5-0.9 ng/mL: 60% 5-year biochemical control rate 2
• Nadir 1.0-1.9 ng/mL: 50% 5-year biochemical control rate 2
• Nadir ≥2.0 ng/mL: Only 17% 5-year biochemical control rate 2

Patients who achieve a nadir ≤0.4 ng/mL AND require ≥2.0 years to reach this nadir have the highest probability of cure—in one series, all 52 such patients maintained biochemical control. 2

Multi-Institutional Data Confirms:

• Nadir <0.5 ng/mL: 75% 8-year biochemical control and 97% distant metastasis-free survival 3
• Nadir 0.5-<1.0 ng/mL: 52% 8-year biochemical control and 96% distant metastasis-free survival 3
• Nadir 1.0-<2.0 ng/mL: 40% 8-year biochemical control and 91% distant metastasis-free survival 3

Current Status at One Year Post-Treatment

Your patient's PSA of 1.6 ng/mL at 12 months is still in the declining phase and has not yet reached nadir. 1, 2

• The median PSA nadir for patients who maintain long-term control is 0.6 ng/mL 2
• PSA values can continue declining for up to 12 months or longer after external beam therapy 4
• Transient PSA rises ("benign bounces") occur in 12-61% of cases between 18-36 months after treatment and should not be immediately interpreted as failure 1

Definition of Biochemical Failure (When to Worry)

Biochemical failure after radiation therapy is defined by the Phoenix Consensus criteria as a PSA rise of ≥2.0 ng/mL above the nadir value. 1

• The older ASTRO definition (three consecutive PSA rises starting ≥2 years after radiation) has been largely replaced by the Phoenix criteria 1
• A minimum interval of 3 months between PSA measurements is recommended to distinguish true progression from benign fluctuations 1
• Isolated PSA increases should be interpreted with caution—serial measurements over 9-12 months are needed to differentiate benign bounces from true recurrence 1

Common Pitfalls to Avoid

• Do not diagnose failure prematurely: A PSA of 1.6 ng/mL at one year does not indicate failure; the nadir has not yet been reached 1, 2
• Do not use absolute PSA thresholds alone: Values between 1.5-3.0 ng/mL require observation until there is unequivocal evidence of a rising pattern 5
• Beware of PSA bounces: Transient rises are common 18-36 months post-treatment and do not necessarily indicate recurrence 1
• Monitor the trend, not single values: PSA kinetics (doubling time, velocity) are more informative than isolated measurements 5, 4

Recommended Monitoring Strategy

Continue PSA monitoring every 3-6 months to document the nadir and subsequent trend. 1, 6

• If PSA continues to decline over the next 6-18 months to ≤0.7 ng/mL, prognosis is favorable 1, 2
• If PSA stabilizes above 1.0 ng/mL but remains stable (not rising), observe closely with serial measurements 5
• Only declare biochemical failure if PSA rises ≥2.0 ng/mL above the eventual nadir on confirmatory testing 1